{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Hits New 52-Week High of $2.68
Lexicon Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting strong performance in the pharmaceuticals sector. The company has experienced significant growth in stock value and net sales over the past year, demonstrating resilience with positive results for six consecutive quarters and high institutional holdings.
Lexicon Pharmaceuticals Hits Day High with 15.28% Surge in Stock Performance
Lexicon Pharmaceuticals, Inc. has seen notable stock activity, achieving significant gains over various timeframes. The company reported a remarkable increase in net sales and has maintained positive financial results for six consecutive quarters. With a market capitalization of USD 702 million, it attracts considerable institutional interest.
Lexicon Pharmaceuticals Hits New 52-Week High of $2.67
Lexicon Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting strong performance in the pharmaceuticals sector. The company reported a 284.16% increase in net sales year-over-year and has shown consistent growth over six quarters, despite being loss-making. High institutional holdings further highlight its market presence.
Lexicon Pharmaceuticals Hits Day Low of $1.88 Amid Price Pressure
Lexicon Pharmaceuticals, Inc. saw a notable decline in its stock today, contrasting with the S&P 500's modest gain. Despite recent downturns, the company has experienced substantial growth over the past year, with significant increases in net sales and quarterly growth, though long-term performance shows challenges.
Lexicon Pharmaceuticals Achieves 107.99% Annual Return, Establishing It as a Multibagger Stock
Lexicon Pharmaceuticals, Inc. has recently undergone a revision in its score, reflecting its strong performance metrics and market position. The stock has outperformed the S&P 500 significantly over the past year, showcasing resilience and growth potential. Positive quarterly results and high institutional holdings further bolster its standing in the biotechnology sector.
Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Lexicon Pharmaceuticals shows a bullish trend supported by strong daily moving averages and a year-to-date return of 80.09%, though it has underperformed over the past three years with a return of -37.85%.
Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Lexicon Pharmaceuticals, Inc. shows a bullish technical trend with strong moving averages and Bollinger Bands, despite mixed signals from KST and OBV indicators, and has significantly outperformed the S&P 500 year-to-date.
Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Lexicon Pharmaceuticals, Inc. shows a bullish trend supported by positive daily moving averages and monthly Bollinger Bands, despite mixed signals from KST and OBV indicators.
Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Lexicon Pharmaceuticals shows a bullish technical trend with strong year-to-date performance of 86.87%, despite mixed signals from some indicators and a longer-term underperformance of -29.23% over the past year.
Is Lexicon Pharmaceuticals, Inc. overvalued or undervalued?
As of October 15, 2023, Lexicon Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 12.5, a P/B ratio of 1.8, and a D/E ratio of 0.3, indicating a solid financial position compared to peers like Amgen and Gilead, and its stock performance has outpaced the Sensex.
Is Lexicon Pharmaceuticals, Inc. technically bullish or bearish?
As of October 1, 2023, there is not enough technical data for Lexicon Pharmaceuticals, Inc. to determine if it is bullish or bearish.
Who are in the management team of Lexicon Pharmaceuticals, Inc.?
As of March 2022, the management team of Lexicon Pharmaceuticals, Inc. includes Mr. Lonnel Coats (CEO), Mr. Raymond Debbane (Chairman), and several independent directors: Mr. Philippe Amouyal, Dr. Samuel Barker, Dr. Robert Lefkowitz, Dr. Alan Nies, and Mr. Frank Palantoni. They oversee the company's strategic direction and operations.
What does Lexicon Pharmaceuticals, Inc. do?
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for human diseases, with a market cap of approximately $262.81 million. As of March 2025, it reported net sales of $1 million and a net loss of $25 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
